Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Christopher L. Wolfgang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-5817-6146; OpenAlex author ID A5051619233; NIH RePORTER profile ID 8653128. Sources: OpenAlex.

Their work

Papers
56 (first author 0, last author 6)
Trials
0
Grants
1
Labs led
1
Collaborators
262
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 6 papers · 2022: 8 papers · 2023: 8 papers · 2024: 8 papers · 2025: 13 papers · 2026: 2 papers, 1 grant

Papers 50 of 56

  1. Incidental Diagnosis of Pancreatic Cancer and Association with Improved Patient Outcomes: Assessing the Potential Clinical Use of Liquid Biopsy-Based Screening… Co-author DOI 10.1097/xcs.0000000000001721↗
  2. Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-336117↗
  3. Longitudinal assessment of disparities in pancreatic cancer care: A retrospective analysis of the National Cancer Database. Co-author DOI 10.1002/wjs.12431↗
  4. Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A prevalence meta-analysis. Co-author DOI 10.1016/j.ejso.2025.109742↗
  5. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  6. Moving Beyond the Standard Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.semradonc.2025.08.001↗
  7. Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. Co-author DOI 10.1093/jnci/djaf037↗
  8. Surgical Resection of Murine PDAC Alters Hepatic Metastases and Immune Microenvironment. Co-author DOI 10.1097/mpa.0000000000002516↗
  9. Defining the Minimal and Optimal Thresholds for Lymph Node Resection and Examination for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: A M… Co-author DOI 10.1097/sla.0000000000006295↗
  10. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  11. Transitional Subtype of Circulating Tumor Cells in Early Post-Operative Period of 5-Year Survivors Following Resection of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000006925↗
  12. Reply to: Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Addressing Statistical and Methodological Concer… Last author DOI 10.1200/jco-24-02598↗
  13. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z↗
  14. Two-Stage Mayo Clinic Class IIIb Celiac Axis Resection for Pancreatic Adenocarcinoma: Stepwise Management. Last author DOI 10.1245/s10434-024-16673-z↗
  15. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  16. The Significance of Circulating Tumor Cells in Pancreatic Cancer. Last author DOI 10.1016/j.yasu.2024.05.001↗
  17. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Last author DOI 10.1097/sla.0000000000006538↗
  18. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686↗
  19. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  20. Consensus, debate, and prospective on pancreatic cancer treatments. Co-author DOI 10.1186/s13045-024-01613-x↗
  21. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  22. Predictors for Long-Term Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Co-author DOI 10.1245/s10434-024-15281-1↗
  23. ASO Author Reflections: The Role of Established Prognostic Factors in Long-Term Survival After Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15391-w↗
  24. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Co-author DOI 10.1002/jhbp.1303↗
  25. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05476-w↗
  26. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. Co-author DOI 10.1016/j.ejso.2023.04.009↗
  27. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  28. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  29. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  30. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000004915↗
  31. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Last author DOI 10.1097/sla.0000000000005710↗
  32. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarc… Co-author DOI 10.1001/jamasurg.2022.1362↗
  33. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  34. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  35. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Co-author DOI 10.1016/j.canlet.2022.215722↗
  36. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  37. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  38. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  39. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  40. A Rare Case of Subcutaneous Insulin Resistance Presumed to be due to Paraneoplastic Process in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.aace.2021.06.001↗
  41. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  42. Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗
  43. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  44. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  45. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Co-author DOI 10.20892/j.issn.2095-3941.2020.0273↗
  46. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2019.10.036↗
  47. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  48. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-18-4192↗
  49. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-19-0094↗
  50. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated Wit… Co-author DOI 10.1016/j.ijrobp.2017.10.001↗

Grants 1

  1. Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas R01CA182076↗

Closest collaborators

The 25 strongest of 262 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ammar A. Javed · 25 shared papers, 2021–2026 · strength 5.39
  2. Joseph R. Habib · 18 shared papers, 2022–2026 · strength 3.92
  3. Jin Peng He · 26 shared papers, 2018–2025 · strength 3.59
  4. Marc G. Besselink · 12 shared papers, 2022–2025 · strength 2.17
  5. Richard Andrew Burkhart · 17 shared papers, 2019–2024 · strength 2.06
  6. Greg D. Sacks · 9 shared papers, 2024–2025 · strength 1.96
  7. Benedict Kinny‐Köster · 13 shared papers, 2022–2025 · strength 1.93
  8. Lei Zheng · 18 shared papers, 2015–2024 · strength 1.80
  9. Ingmar Florin Rompen · 8 shared papers, 2024–2025 · strength 1.67
  10. Lois A. Daamen · 9 shared papers, 2023–2025 · strength 1.64
  11. Izaak Quintus Molenaar · 9 shared papers, 2023–2025 · strength 1.64
  12. Kelly J. Lafaro · 10 shared papers, 2022–2025 · strength 1.53
  13. Elizabeth M. Jaffee · 17 shared papers, 2013–2025 · strength 1.51
  14. Daniel Brock Hewitt · 7 shared papers, 2024–2025 · strength 1.47
  15. Mahip Grewal · 7 shared papers, 2024–2025 · strength 1.46
  16. William R. Burns · 10 shared papers, 2021–2023 · strength 1.33
  17. Jun Yu · 9 shared papers, 2021–2024 · strength 1.15
  18. Paul C. M. Andel · 6 shared papers, 2024–2025 · strength 1.12
  19. Jing He · 5 shared papers, 2023–2026 · strength 1.08
  20. Daniel A. Laheru · 12 shared papers, 2013–2025 · strength 1.07
  21. Carlos Fernandez-Del Castillo · 1 shared grant, 2026 · strength 1.00
  22. Peter J. Allen · 1 shared grant, 2026 · strength 1.00
  23. Amol Kumar Narang · 8 shared papers, 2018–2025 · strength 1.00
  24. Brady A. Campbell · 5 shared papers, 2024–2025 · strength 0.95
  25. Ding Ding · 7 shared papers, 2021–2023 · strength 0.90

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.